<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03205917</url>
  </required_header>
  <id_info>
    <org_study_id>IAVI T002</org_study_id>
    <nct_id>NCT03205917</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of PGDM1400 and PGT121 Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults</brief_title>
  <official_title>A Phase 1 Randomized Placebo-controlled Clinical Trial of the Safety, Pharmacokinetics and Antiviral Activity of PGDM1400 and PGT121 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International AIDS Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ragon Institute of MGH, MIT and Harvard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International AIDS Vaccine Initiative</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and anti-viral
      efficacy of the PGDM1400 and PGT121 mAbs for HIV prevention and therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and anti-viral
      efficacy of the PGDM1400 and PGT121 mAbs for HIV prevention and therapy. PGDM1400 mAb and
      PGT121 mAb are recombinant human IgG1 monoclonal antibodies that target a V1V2 (PGDM1400) and
      a V3 glycan-dependent (PGT121) epitope region of the HIV envelope protein (Jardine, Julien et
      al. 2013, Sok, Doores et al. 2014). PGT121 and PGDM1400 mAb were chosen for this study
      because they are potent, neutralize a wide array of HIV viruses, and can prevent and treat
      simian-human immunodeficiency virus (SHIV) in rhesus monkeys.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with PGDM1400 and/or PGT121 related AE, SAEs and reactogenicity</measure>
    <time_frame>6 Months post infusion</time_frame>
    <description>Proportion of participants with moderate or greater reactogenicity (e.g., solicited adverse events) following IV infusion of PGDM1400 ± PGT121 mAb.
Proportion of participants with adverse events (AEs), including safety laboratory (biochemical, hematological) parameters following IV infusion of PGDM1400 ± PGT121 mAb that are moderate or greater and/or related to PGDM1400 or PGT121 mAb.
Proportion of participants with serious adverse events (SAEs) throughout the study period following IV infusion of PGDM1400 ± PGT121 mAb that are related to PGDM1400 or PGT121 mAb.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of PGDM1400 mAb alone or a combination of PGDM1400 mAb and PGT121 mAb in HIV-uninfected and HIV-infected adults- elimination half-life (t1/2)</measure>
    <time_frame>6 Months post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of PGDM1400 mAb alone or a combination of PGDM1400 mAb and PGT121 mAb in HIV-uninfected and HIV-infected adults- clearance (CL/F)</measure>
    <time_frame>6 Months post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of PGDM1400 mAb alone or a combination of PGDM1400 mAb and PGT121 mAb in HIV-uninfected and HIV-infected adults- volume of distribution (Vz/F)</measure>
    <time_frame>6 Months post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of PGDM1400 mAb alone or a combination of PGDM1400 mAb and PGT121 mAb in HIV-uninfected and HIV-infected adults- area under the concentration decay curve (AUC)</measure>
    <time_frame>6 Months post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of viral load on PGDM1400 mAb and PGT121 mAb disposition (elimination half-life (t1/2), clearance (CL/F), volumne of distribution (Vz/F), total exposure</measure>
    <time_frame>6 Months post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma HIV-1 RNA levels from baseline (mean of pre-entry and entry values)</measure>
    <time_frame>6 Months post infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group 1A (PGDM1400/Placebo )</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-Uninfected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1B (PGDM1400/Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-Uninfected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1C (PGDM1400/Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-Uninfected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2A (PGDM1400 + PGT121/Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-Uninfected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2B (PGDM1400 + PGT121/Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-Uninfected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2C (PGDM1400 + PGT121/Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-Uninfected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3A (PGDM1400 )</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected off ART (VL 2x103 - 1x105 copies/ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3B (PGDM1400+PGT121 )</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected off ART (VL 2x103 - 1x105 copies/ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGDM1400/Placebo - 3mg/mL IV</intervention_name>
    <description>3/1 (6/2 if DLT); 3mg/mL IV</description>
    <arm_group_label>Group 1A (PGDM1400/Placebo )</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGDM1400/Placebo - 310mg/mL IV</intervention_name>
    <description>3/1 (6/2 if DLT); 10mg/mL IV</description>
    <arm_group_label>Group 1B (PGDM1400/Placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGDM1400/Placebo -30mg/mL IV</intervention_name>
    <description>3/1 (6/2 if DLT); 30mg/mL IV</description>
    <arm_group_label>Group 1C (PGDM1400/Placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGDM1400 + PGT121/Placebo - 3mg/mL + 3mg/mL IV</intervention_name>
    <description>3/1 (6/2 if DLT); 3mg/mL + 3mg/mL IV</description>
    <arm_group_label>Group 2A (PGDM1400 + PGT121/Placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGDM1400 + PGT121/Placebo - 10mg/mL + 10mg/mL IV</intervention_name>
    <description>3/1 (6/2 if DLT); 10mg/mL + 10mg/mL IV</description>
    <arm_group_label>Group 2B (PGDM1400 + PGT121/Placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGDM1400 + PGT121/Placebo - 30mg/mL + 30mg/mL IV</intervention_name>
    <description>3/1 (6/2 if DLT); 30mg/mL + 30mg/mL IV</description>
    <arm_group_label>Group 2C (PGDM1400 + PGT121/Placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGDM1400</intervention_name>
    <description>6 (max 18); MTD IV</description>
    <arm_group_label>Group 3A (PGDM1400 )</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGDM1400+PGT121</intervention_name>
    <description>6 (max 18); MTD IV</description>
    <arm_group_label>Group 3B (PGDM1400+PGT121 )</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Group 1 and 2 Inclusion Criteria:

        • Willing to maintain low risk behavior for HIV infection

        Group 1 and 2 Exclusion Criteria:

        • confirmed HIV-infection, pregnancy or lactation, significant acute or chronic disease and
        clinically significant laboratory abnormalities

        Group 3 Inclusion Criteria:

        • HIV-infected males or females not on antiretroviral therapy with HIV-1 RNA plasma level
        between 1,000 and 100,000 copies/ml, CD4 cell count ≥ 300 cells/uL

        Group 3 Exclusion Criteria:

        • Significant acute or chronic medical condition other than HIV infection, and clinically
        significant laboratory abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris Juleg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center, Center for Virology and Vaccine Research, Ragon Institute of MGH, MIT and Harvard</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathryn Stephenson, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Beth Israel Deaconess Medical Center, Center for Virology and Vaccine Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frances Priddy, MD, MPH</last_name>
    <phone>+1-212-328-7461</phone>
    <email>fpriddy@iavi.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beth Isreal Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris D Juelg, MD, PhD</last_name>
      <phone>857-268-7088</phone>
      <email>bjuelg@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://iavi.org</url>
    <description>IAVI Website</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2017</study_first_submitted>
  <study_first_submitted_qc>June 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

